Short Interest in Pharma Mar (OTCMKTS:PHMMF) Increases By 1,430.8%

Pharma Mar (OTCMKTS:PHMMF) was the recipient of a large growth in short interest during the month of July. As of July 31st, there was short interest totaling 199 shares, a growth of 1,430.8% from the July 15th total of 13 shares. Currently, 0.0% of the shares of the company are sold short. Based on an average daily trading volume, of 15 shares, the days-to-cover ratio is currently 13.3 days.

Pharma Mar Price Performance

PHMMF stock opened at $87.58 on Wednesday. Pharma Mar has a twelve month low of $77.41 and a twelve month high of $110.40. The company has a debt-to-equity ratio of 0.14, a current ratio of 3.02 and a quick ratio of 2.44. The business’s 50-day simple moving average is $87.24 and its 200 day simple moving average is $93.68.

Wall Street Analysts Forecast Growth

PHMMF has been the subject of a number of research analyst reports. Zacks Research upgraded Pharma Mar to a “hold” rating in a report on Monday, June 15th. BTIG Research started coverage on shares of Pharma Mar in a research note on Thursday, April 23rd. They issued a “buy” rating on the stock. Finally, Chardan Capital raised shares of Pharma Mar to a “strong-buy” rating in a research report on Tuesday, June 9th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, Pharma Mar has an average rating of “Buy”.

About Pharma Mar

PharmaMar is a Spain-based biopharmaceutical company that specializes in the discovery and development of novel oncology therapies derived from marine organisms. Founded in 1986 as part of Grupo Zeltia, the company has pioneered the use of compounds extracted from deep-sea organisms to create synthetic analogs aimed at treating various forms of cancer. Its core expertise lies in marine biotechnology, medicinal chemistry and oncology-focused clinical development.

The company’s flagship product is Yondelis (trabectedin), an antitumor agent approved in the European Union for the treatment of soft tissue sarcoma and relapsed platinum-sensitive ovarian cancer.